Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (Nasdaq: RXRX) reported Q1 2026 results and business progress on May 6, 2026. Key clinical highlights include REC-1245 early Phase 1 safety/PK with no DLTs (n=16), REC-4881 Phase 2 polyp reductions (median 43% at Week 13, 53% at Week 25), and first patient dosed in REC-4539. Financials: cash $665.2M (Mar 31, 2026), revenue $6.5M, net loss $117.5M. Company reiterates 2026 operational cash burn <$390M and expects runway into early 2028 without additional financing.
Recursion (NASDAQ: RXRX) announced a board transition: founder Chris Gibson, Ph.D. will complete his current term through June 2026 and will not seek re-election to the board, and will continue with the company as a strategic advisor.
CEO Najat Khan reaffirmed a focus on continuity, the company’s internal and partnered pipeline, and translating its AI-powered platform toward therapeutic impact for shareholders and patients.
Recursion (Nasdaq: RXRX) will report first quarter 2026 business updates and financial results on Wednesday, May 6, 2026, before market open. The company will host a public Earnings Call at 8:00 am ET / 6:00 am MT / 1:00 pm BST and stream live on Recursion's X, LinkedIn, and YouTube accounts. Investors may submit questions via the company form link provided.
Recursion (Nasdaq: RXRX) will participate in two upcoming investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, and the Bank of America Health Care Conference 2026 on May 12, 2026. Webcasts will be available in the company events section at ir.recursion.com.
Recursion (Nasdaq: RXRX) named Vicki Goodman, M.D. as Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D., who will transition from the role after approximately three years.
Recursion highlighted Dr. Goodman’s late‑stage oncology and regulatory experience as supportive for advancing its clinical pipeline, including ongoing progression of REC‑4881.
Recursion (NASDAQ: RXRX) reported fourth-quarter and full-year 2025 results and a business update highlighting clinical validation of its AI Operating System, material partnered milestone receipts, and a strong cash position. Key points: REC-4881 showed meaningful polyp reductions in FAP, the company holds $754 million in cash, and management expects runway into early 2028.
Recursion achieved a fifth Sanofi milestone, advanced multiple discovery programs, reported revenue growth in 2025, and delivered operating efficiencies with 2025 cash operating expense near $399 million.
Recursion (Nasdaq: RXRX) will be featured in HighRes’ Lightning Talk at NVIDIA GTC March 16–19, 2026 in San Jose. The session highlights AI agents, robotics, and digital twins supporting self-driving, high-throughput labs and biomanufacturing.
Presenters include HighRes CEO Ira Hoffman, NVIDIA moderator Stacie Calad-Thomson, and representatives from Multiply Labs and Thermo Fisher. Recursion says it operates integrated wet and dry labs, generates millions of multi-omic data points weekly, and leverages its NVIDIA-backed supercomputer BioHive-2 to train ML models for drug discovery.
Recursion (Nasdaq: RXRX) will participate in multiple investor conferences in March 2026, presenting company updates and management outlooks.
Scheduled events include TD Cowen (March 2), Leerink Partners (March 9), Jefferies Biotech on the Beach (March 11), and KeyBanc Healthcare Forum (March 17). Webcasts are available in the events section at the company investor relations site.
Recursion (Nasdaq: RXRX) will report fourth quarter and full year 2025 business updates and financial results on Wednesday, February 25, 2026, before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube accounts, and investors may submit questions in advance via the company’s online form.
Recursion (NASDAQ: RXRX) announced that on February 6, 2026 its Compensation Committee approved inducement restricted stock unit awards covering 820,431 shares of Class A common stock granted to 17 new employees under the 2024 Inducement Equity Incentive Plan.
Each RSU vests 25% at the first quarterly vesting date on or after the one-year anniversary of the vesting commencement date, then vests at 1/16th each quarter thereafter, subject to continued employment and plan/grant agreement terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).